SWOG Cancer Research Network
Saruparib(SWOG Cancer Research Network)은 Prostate Cancer 표적 치료제로, Extensive Stage Lung Small Cell Carcinoma; Lung Small Cell Carcinoma, A Subtype 영역에서 개발·상용화 중입니다. 작용기전: target-site mutation over pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 13건의 관련 임상이 등록되어 있습니다. PK: t½ 22.5 h. 차별점: first-in-class PARP1-specific inhibitor, promotes the release of certain PARP1 catalytic mutants and resistance to this inhibitor.
Prostate Cancer
Extensive Stage Lung Small Cell Carcinoma; Lung Small Cell Carcinoma, A Subtype
Recruiting
ADC) allow the delivery of cytotoxic chemotherapeutic agents to
vedotin plus pembrolizumab (KEYNOTE-905/EV-303)
linker optimization, CPP-13, a pomalidomide-based degrader with a 13-atom linker, was
first-in-class PARP1-specific inhibitor, promotes the release of certain PARP1 catalytic mutants and resistance to this inhibitor
target-site mutation over pathway
DNA damage response-targeted therapy: Mechanisms, predictive biomarkers, and biomarker-guided adaptive treatment strategies in sol
biomarkers, and biomarker-guided adaptive treatment strategies in solid tumors
resistance to this inhibitor
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
SWOG Cancer Research Network
Saruparib(SWOG Cancer Research Network)은 Prostate Cancer 표적 치료제로, Extensive Stage Lung Small Cell Carcinoma; Lung Small Cell Carcinoma, A Subtype 영역에서 개발·상용화 중입니다. 작용기전: target-site mutation over pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 13건의 관련 임상이 등록되어 있습니다. PK: t½ 22.5 h. 차별점: first-in-class PARP1-specific inhibitor, promotes the release of certain PARP1 catalytic mutants and resistance to this inhibitor.
Prostate Cancer
Extensive Stage Lung Small Cell Carcinoma; Lung Small Cell Carcinoma, A Subtype
Recruiting
ADC) allow the delivery of cytotoxic chemotherapeutic agents to
vedotin plus pembrolizumab (KEYNOTE-905/EV-303)
linker optimization, CPP-13, a pomalidomide-based degrader with a 13-atom linker, was
first-in-class PARP1-specific inhibitor, promotes the release of certain PARP1 catalytic mutants and resistance to this inhibitor
target-site mutation over pathway
DNA damage response-targeted therapy: Mechanisms, predictive biomarkers, and biomarker-guided adaptive treatment strategies in sol
biomarkers, and biomarker-guided adaptive treatment strategies in solid tumors
resistance to this inhibitor
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.